Axsome's Auvelity Receives FDA Label Expansion for Alzheimer’s Agitation

Axsome Therapeutics has secured FDA approval for an expanded label for its drug Auvelity, allowing it to be used in the treatment of agitation associated with Alzheimer's disease.